Does an Endometrial Cancer Diagnosis among Asymptomatic
Patients Improve Prognosis?

J 2022

Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?

VINKLEROVÁ, Petra, Petra OVESNÁ, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER et. al.

Základní údaje

Originální název

Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?

Autoři

VINKLEROVÁ, Petra (203 Česká republika, domácí), Petra OVESNÁ (203 Česká republika, domácí), Markéta BEDNAŘÍKOVÁ (203 Česká republika, domácí), Luboš MINÁŘ (203 Česká republika, domácí), Michal FELSINGER (203 Česká republika, domácí), Jitka HAUSNEROVÁ (203 Česká republika, domácí) a Vít WEINBERGER (203 Česká republika, garant, domácí)

Vydání

Cancers, Basel, MDPI, 2022, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200

Kód RIV

RIV/00216224:14110/22:00125126

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/cancers14010115

UT WoS

000741365900001

Klíčová slova anglicky

endometrial cancer; postmenopausal bleeding; prognosis

Štítky

14110212, 14110230, 14110411, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 7. 2022 09:29, Mgr. Tereza Miškechová

Anotace

V originále

Background: Endometrial cancer is the most common gynecological malignancy in developed countries with no screening available. There is still a tendency to provide invasive bioptic verification in asymptomatic women with abnormal ultrasound findings to diagnose carcinoma in a preclinical phase; even though, it is not supported by European guidelines. Our goal was to determine DFS (disease-free survival), OS (overall survival), and DSS (disease-specific survival) differences between symptom-free and symptomatic (bleeding, or spotting) endometrial cancer patients with similar stage and tumor/clinical characteristics. Methods: All of our patients with endometrial cancer following surgical treatment between 2006 and 2019 were assessed, evaluating risk factors for recurrence and death while focusing on bleeding using univariable and multivariable analysis. Results: 625 patients meeting the inclusion criteria were divided into asymptomatic (n = 144, 23%) and symptomatic (n = 481, 77%) groups. The median follow-up was 3.6 years. Using univariable analysis, symptomatic patients had a three times higher risk of recurrence (HR 3.1 (95% Cl 1.24–7.77), p = 0.016). OS (HR 1.35 (0.84–2.19), p = 0.219) and DSS (HR 1.66 (0.64–4.28), p = 0.3) were slightly worse without reaching statistical significance. In our multivariable analysis, symptomatology was deemed completely insignificant in all monitored parameters (DFS: HR 2.03 (0.79–5.24), p = 0.144; OS: HR 0.72 (0.43–1.21), p = 0.216). Conclusions: The symptomatic endometrial cancer patients risk factor of earlier recurrence and death is insignificantly higher when compared with the asymptomatic cohort. However, multivariable analysis verifies that prognosis worsens with other clinically relevant parameters, not by symptomatology itself. In terms of survival outcome in EC patients, we recognized symptomatology as a non-significant marker for the patient’s prognosis.

Citovat

VINKLEROVÁ, Petra, Petra OVESNÁ, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Jitka HAUSNEROVÁ a Vít WEINBERGER. Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis? Cancers. Basel: MDPI, 2022, roč. 14, č. 1, s. 1-11. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers14010115.

@article{1816307,
   author = {Vinklerová, Petra and Ovesná, Petra and Bednaříková, Markéta and Minář, Luboš and Felsinger, Michal and Hausnerová, Jitka and Weinberger, Vít},
   article_location = {Basel},
   article_number = {1},
   doi = {http://dx.doi.org/10.3390/cancers14010115},
   keywords = {endometrial cancer; postmenopausal bleeding; prognosis},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?},
   url = {https://www.mdpi.com/2072-6694/14/1/115},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 1816307
AU  - Vinklerová, Petra - Ovesná, Petra - Bednaříková, Markéta - Minář, Luboš - Felsinger, Michal - Hausnerová, Jitka - Weinberger, Vít
PY  - 2022
TI  - Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?
JF  - Cancers
VL  - 14
IS  - 1
SP  - 1-11
EP  - 1-11
PB  - MDPI
SN  - 20726694
KW  - endometrial cancer
KW  - postmenopausal bleeding
KW  - prognosis
UR  - https://www.mdpi.com/2072-6694/14/1/115
N2  - Background: Endometrial cancer is the most common gynecological malignancy in developed countries with no screening available. There is still a tendency to provide invasive bioptic verification in asymptomatic women with abnormal ultrasound findings to diagnose carcinoma in a preclinical phase; even though, it is not supported by European guidelines. Our goal was to determine DFS (disease-free survival), OS (overall survival), and DSS (disease-specific survival) differences between symptom-free and symptomatic (bleeding, or spotting) endometrial cancer patients with similar stage and tumor/clinical characteristics. Methods: All of our patients with endometrial cancer following surgical treatment between 2006 and 2019 were assessed, evaluating risk factors for recurrence and death while focusing on bleeding using univariable and multivariable analysis. Results: 625 patients meeting the inclusion criteria were divided into asymptomatic (n = 144, 23%) and symptomatic (n = 481, 77%) groups. The median follow-up was 3.6 years. Using univariable analysis, symptomatic patients had a three times higher risk of recurrence (HR 3.1 (95% Cl 1.24–7.77), p = 0.016). OS (HR 1.35 (0.84–2.19), p = 0.219) and DSS (HR 1.66 (0.64–4.28), p = 0.3) were slightly worse without reaching statistical significance. In our multivariable analysis, symptomatology was deemed completely insignificant in all monitored parameters (DFS: HR 2.03 (0.79–5.24), p = 0.144; OS: HR 0.72 (0.43–1.21), p = 0.216). Conclusions: The symptomatic endometrial cancer patients risk factor of earlier recurrence and death is insignificantly higher when compared with the asymptomatic cohort. However, multivariable analysis verifies that prognosis worsens with other clinically relevant parameters, not by symptomatology itself. In terms of survival outcome in EC patients, we recognized symptomatology as a non-significant marker for the patient’s prognosis.
ER  -

VINKLEROVÁ, Petra, Petra OVESNÁ, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Jitka HAUSNEROVÁ a Vít WEINBERGER. Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis? \textit{Cancers}. Basel: MDPI, 2022, roč.~14, č.~1, s.~1-11. ISSN~2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers14010115.

Podrobný výpis o publikaci